Successful treatment of recalcitrant hidradenitis suppurativa with risankizumab after failure of anti-tumour necrosis factor alpha
Language English Country England, Great Britain Media print-electronic
Document type Letter, Research Support, Non-U.S. Gov't
Grant support
PROGRES Q28 (oncology) research program awarded by the Charles University, Prague
PubMed
33301601
DOI
10.1111/bjd.19716
Knihovny.cz E-resources
- MeSH
- Hidradenitis Suppurativa * drug therapy MeSH
- Humans MeSH
- Antibodies, Monoclonal therapeutic use MeSH
- Tumor Necrosis Factor-alpha MeSH
- Check Tag
- Humans MeSH
- Publication type
- Letter MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Antibodies, Monoclonal MeSH
- risankizumab MeSH Browser
- Tumor Necrosis Factor-alpha MeSH
See more in PubMed
Cubilla JAG, Martinez Zugaib Abdalla B, Ricardo Criado P, Keiko Oyafuso L. Immunological pathways in hidradenitis suppurativa: current concepts and innovative therapies. J Clin Res Dermatology 2018; 5:1-7.
Arenbergerova M, Arenberger P, Marques E, Gkalpakiotis S. Successful treatment of recalcitrant gluteal hidradenitis suppurativa with brodalumab after anti-TNF failure. Int J Dermatol 2020; 59:733-5.
Kok Y, Nicolopoulos J, Howard A et al. Tildrakizumab in the treatment of moderate-to-severe hidradenitis suppurativa. Australas J Dermatol 2020; 61:e488-90.
Casseres RG, Kahn JS, Her MJ, Rosmarin D. Guselkumab in the treatment of hidradenitis suppurativa: a retrospective chart review. J Am Acad Dermatol 2019; 81:265-7.
Montero-Vilchez T, Pozo-Román T, Sánchez-Velicia L et al. Ustekinumab in the treatment of patients with hidradenitis suppurativa: multicenter case series and systematic review. J Dermatolog Treat 2020; https://doi.org/10.1080/09546634.2020.1755008.
Summary of Product Characteristics. Skyrizi (risankizumab). Available at: https://www.ema.europa.eu/en/documents/product-information/skyrizi-epar-product-information_en.pdf (last accessed 25 December 2020).
Chang S, Chambers CJ, Liu FT, Armstrong AW. Successful treatment of psoriasis with ustekinumab in patients with multiple sclerosis. Dermatol Online J 2015; 21:13030/qt3bs971cr.
Wong D, Walsh S, Alhusayen R. Low-dose systemic corticosteroid treatment for recalcitrant hidradenitis suppurativa. J Am Acad Dermatol 2016; 75:1059-62.
